Martin Samuel Bates 4

What Happened

• Martin Samuel Bates, SVP and Chief Financial Officer of Celldex Therapeutics (CLDX), received a grant of 93,000 derivative securities (an option award) on June 25, 2026. The Form 4 reports an acquisition price of $0.00 for the award; the filing footnote identifies the award as an option granted under Celldex’s 2021 Omnibus Equity Incentive Plan. This is a compensation grant (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-06-25. Form 4 filed: 2026-06-29 (timely; within the required two business days).
• Transaction type: Grant / derivative (option award).
• Securities granted: 93,000 shares (options).
• Price reported on Form 4: $0.00 (award/grant reporting); exercise price is not shown in the excerpt.
• Vesting: 25% vests on June 25, 2027; remaining 75% vests in equal quarterly installments over the following 12 quarters (i.e., full vesting over four years).
• Plan: 2021 Omnibus Equity Incentive Plan (per footnote).
• Shares beneficially owned after the transaction: not stated in the provided filing excerpt.

Context

• This is a standard equity compensation award intended to retain and incentivize an executive; it is not an immediate purchase of stock and does not represent a sale. Options give the holder the right to buy shares in the future at a specified exercise price (which would be disclosed in full SEC filings or the company’s grant paperwork). Watch for future Form 4 filings if/when the options are exercised or shares are sold.